BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approach First evaluated candidate BNT165b1 expresses certain parts of the circumsporozoite protein (CSP) BNT165 program will assess other …